Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vardenafil Hydrochloride

FDA-approved product (tablet, oral), marketed as Levitra, Staxyn, Vardenafil Hydrochloride.

Registered studies
7
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vardenafil Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Erectile dysfunction
  • Impotence

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs used in erectile dysfunction
FDA pharmacologic class
Phosphodiesterase 5 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

7registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vardenafil Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vardenafil Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

    NCT05343637 · start 2019-07-30

    Registered record
    Registry ID
    NCT05343637
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-07-30
    Completion
    2020-01-17
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionDrug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
    PhasePhase 2
    Registry statusCompleted

  • A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234

    NCT05567367 · start 2018-07-31

    Registered record
    Registry ID
    NCT05567367
    Conditions
    Healthy Volunteer
    Interventions
    Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI); Vardenafil Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-07-31
    Completion
    2019-12-04
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionDrug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI); Vardenafil Oral Tablet
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients

    NCT03102398 · start 2017-03-31

    Registered record
    Registry ID
    NCT03102398
    Conditions
    Erectile Dysfunction
    Interventions
    TR-399 (5% Vardenafil HCl·3H2O, topical gel)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2017-03-31
    Completion
    2018-03-31
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionTR-399 (5% Vardenafil HCl·3H2O, topical gel)
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction

    NCT01063855 · start 2010-04

    Registered record
    Registry ID
    NCT01063855
    Conditions
    Erectile Dysfunction; Sexual Dysfunction
    Interventions
    Placebo; Dapoxetine; PDE5I (phosphodiesterase-5 inhibitor)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-04
    Completion
    2011-09
    Enrolment
    495

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction; Sexual Dysfunction
    InterventionPlacebo; Dapoxetine; PDE5I (phosphodiesterase-5 inhibitor)
    PhasePhase 3
    Registry statusCompleted

  • A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function

    NCT00478881 · start 2007-08

    Registered record
    Registry ID
    NCT00478881
    Conditions
    Overactive Bladder; Detrusor Overactivity
    Interventions
    Vardenafil HCl (Levitra, BAY38-9456); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-08
    Completion
    2008-11
    Enrolment
    397

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder; Detrusor Overactivity
    InterventionVardenafil HCl (Levitra, BAY38-9456); Placebo
    PhasePhase 2
    Registry statusCompleted

  • Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED)

    NCT00665340 · start 2004-07

    Registered record
    Registry ID
    NCT00665340
    Conditions
    Erectile Dysfunction
    Interventions
    Placebo; Levitra (Vardenafil, BAY38-9456)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-07
    Completion
    2005-01
    Enrolment
    219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionPlacebo; Levitra (Vardenafil, BAY38-9456)
    PhasePhase 4
    Registry statusCompleted

  • BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.

    NCT00668057 · start 2002-12

    Registered record
    Registry ID
    NCT00668057
    Conditions
    Erectile Dysfunction
    Interventions
    Levitra (Vardenafil, BAY38-9456); Levitra (Vardenafil, BAY38-9456); Levitra (Vardenafil, BAY38-9456); Placebo; Placebo; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-12
    Completion
    2003-09
    Enrolment
    624

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionLevitra (Vardenafil, BAY38-9456); Levitra (Vardenafil, BAY38-9456); Levitra (Vardenafil, BAY38-9456); Placebo +2 more
    PhasePhase 3
    Registry statusCompleted